Korean Circ J.  2007 Jan;37(1):22-26. 10.4070/kcj.2007.37.1.22.

Clinical Outcomes of Cobalt-Chromium Alloy ArthosPico Stent for Native Coronary Lesions

• Kim HS
• Kim YH
• Oh SJ
• Yang JY
• Ko JK
• Lee CW
• Hong MK
• Kim JJ
• Park SW
• Park SJ

• KMID: 2227089
• DOI: http://doi.org/10.4070/kcj.2007.37.1.22

Abstract

BACKGROUND AND OBJECTIVES: It has been reported that strut thickness is associated with the occurrence of in-stent restenosis. This prospective, multicenter, single-arm study was designed to evaluate the safety and efficacy of the ArthosPico stent manufactured with thin-strut cobalt-chromium alloy steel for simple de novo coronary lesions.
SUBJECTS AND METHODS
A total of 150 coronary lesions that were > or =3.0 mm in diameter and < or =20 mm in length, which could be covered by a single stent, were enrolled. Clopidogrel was used for 1 month.
RESULTS
Acute coronary syndrome was involved in 60.7% of patients. The right coronary artery (50.0%) was the most common target vessel. All stents were successfully deployed at the target lesions. Reference vessel diameter was 3.1+/-0.5 mm and lesion length was 13.6+/-4.6 mm. Minimal lumen diameter was increased from 1.03+/-0.48 to 3.04+/-0.49 mm after the procedure. Follow-up angiography was obtained in 117 lesions (78%). Binary restenosis was documented in 12.0% of stented segments and in 13.7% of analytic segments. Late luminal loss was found to be 0.78+/-0.75 mm in stented segments and 0.59+/-0.74 mm in analytic segments. During 7.0+/-2.8 months follow-up, cardiac death or non-fatal myocardial infarction occurred in 2 (1.3%) and 2 (1.3%) patients, respectively. Target lesion revascularization was performed in 11 (7.3%) patients.
CONCLUSION
The cobalt-chromium alloy ArthosPico stent for relatively simple coronary lesions showed favorable acute and long-term outcomes in terms of very low incidence of death or myocardial infarction and a single digit rate of target lesion revascularization.

Keyword

Stent; Restenosis; Coronary artery disease

MeSH Terms

Acute Coronary Syndrome
Alloys*
Angiography
Coronary Artery Disease
Coronary Vessels
Death
Follow-Up Studies
Humans
Incidence
Myocardial Infarction
Phenobarbital
Prospective Studies
Steel
Stents*
Alloys
Phenobarbital
Steel

Reference

1. Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med. 2006. 119:1056–1061.

2. Kastrati A, Mehilli J, Dirschinger J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation. 2001. 103:2816–2821.

3. Briguori C, Sarais C, Pagnotta P, et al. In-stent restenosis in small coronary arteries impact of strut thickness. J Am Coll Cardiol. 2002. 40:403–409.

4. Pache J, Kastrati A, Mehilli J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol. 2003. 41:1283–1288.

5. Rittersma SZ, de Winter RJ, Koch KT, et al. Impact of strut thickness on late luminal loss after coronary artery stent placement. Am J Cardiol. 2004. 93:477–480.

6. Kim JY, Yoon J, Jung IH, et al. Comparison of the cobalt alloy and stainless steel core® stent in a porcine coronary restenosis model. Korean Circ J. 2005. 35:507–512.

7. Ellis SG, Vandormael MG, Cowley MJ, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease: implications for patient selection. Circulation. 1990. 82:1193–1202.

8. Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis: classification and implication for long-term outcome. Circulation. 1999. 100:1872–1878.

9. Ryan J, Cohen DJ. Are drug-eluting stents cost-effective?: it depends on whom you ask. Circulation. 2006. 114:1736–1744.

10. Carter AJ, Aggarwal M, Kopia GA, et al. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res. 2004. 63:617–624.

11. Bakhai A, Stone GW, Mahoney E, et al. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial. J Am Coll Cardiol. 2006. 48:253–261.

12. Cohen DJ, Bakhai A, Shi C, et al. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the sirolimus-eluting balloon expandable stent in the treatment of patients with de novo native coronary artery lesions (SIRIUS) trial. Circulation. 2004. 110:508–514.

13. Kaiser C, Brunner-La Rocca HP, et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting. Lancet. 2005. 366:921–929.

14. Kereiakes DJ, Cox DA, Hermiller JB, et al. Usefulness of a cobalt chromium coronary stent alloy. Am J Cardiol. 2003. 92:463–466.

15. Sketch MH Jr, Ball M, Rutherford B, et al. Evaluation of the Medtronic (Driver) cobalt-chromium alloy coronary stent system. Am J Cardiol. 2005. 95:8–12.

16. Legrand V, Kelbaek H, Hauptmann KE, et al. Clinical and angiographic analysis with a cobalt alloy coronary stent (Driver) in stable and unstable angina pectoris. Am J Cardiol. 2006. 97:349–352.

17. Tahk SJ, Choi SY, Choi BJ, et al. The effects of a carbon ion implantation technique on in-stent restenosis. Korean Circ J. 2004. 34:477–484.

18. Kastrati A, Dirschinger J, Boekstegers P, et al. Influence of stent design on 1-year outcome after coronary stent placement: a randomized comparison of five stent types in 1,147 unselected patients. Catheter Cardiovasc Interv. 2000. 50:290–297.